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Therapeutic drug monitoring 
Pharmacokinetics 
A B S T R A C T   
The pharmacokinetic profiling of drug substances and corresponding metabolites in the biological matrix is one 
of the most informative tools for the treatment efficacy assessment. Therefore, to satisfy the need for compre-
hensive monitoring of anti-tuberculosis drugs in human plasma, a liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) method was developed and validated for simultaneous quantification of first-line anti- 
tuberculosis drugs (ethambutol, isoniazid, pyrazinamide, and rifampicin) along with their six primary metabo-
lites. Simple single-step protein precipitation with methanol was chosen as the most convenient sample pre- 
treatment method. Chromatographic separation of the ten analyte mixture was achieved within 10 minutes on 
a reverse-phase C8 column using mobile phase gradient mode. The multiple reaction monitoring mode (MRM) 
was used for analyte detection and quantification in patient samples. The chosen quantification ranges fully 
covered expected plasma concentrations. The method exhibited acceptable selectivity; the within- and between- 
run accuracy ranged from 87.2 to 113.6%, but within- and between-run precision was between 1.6 and 14.9% (at 
the LLOQ level CV < 20%). Although the response of the isonicotinic acid varied depending on the matrix source 
(CV 21.8%), validation results proved that such inconsistency does not affect the accuracy and precision of re-
sults. If stored at room temperature plasma samples should be processed within 4 h after collection, temporary 
storage at − 20 ◦C up to 24 h is acceptable due to stability issues of analytes. The developed method was applied 
for the patient sample analysis (n = 34) receiving anti-tuberculosis treatment with the first-line drugs.   
1. Introduction 
Tuberculosis (TB) is an airborne infectious disease caused by Myco-
bacterium tuberculosis. Despite the current medical development, an 
estimation of 10 million new cases and 1.4 million deaths in 2019 proves 
that TB remains a global health problem [1]. The cure rate of 85% is 
reached using a 6-month standardized treatment regimen consisting of 
four first-line anti-tuberculosis drugs (ethambutol (ETB), pyrazinamide 
(PZA), rifampicin (RIF) and, isoniazid (IZN)) [1,2]. However, 15% of 
patients experience a relapse or develop a drug-resistant form of the 
disease and require treatment prolongation with costly and more toxic 
second-line drugs. Poor treatment adherence, nutrition, comorbidities, 
drug-drug interactions, and even the patient’s genotype may contribute 
to inter-individual differences in drug exposure among TB patients 
[3–10]. The pharmacokinetic profiling of drug substances in various 
biological matrices is an efficient approach to investigate 
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pharmacokinetic variability and to evaluate drug efficiency and the 
outcome of the therapy. At the individual level, interpretation of a pa-
tient’s pharmacokinetic profile as a part of therapeutic drug monitoring 
(TDM) program allows to assess the dosing regime and decide whether a 
transition from standardized to personalized treatment strategy could 
improve treatment outcome [3,10–13]. 
The liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
is the most utilised analytical technique for the TDM in research labo-
ratories and has become the method of choice in the clinical setting. In 
the past years, numerous reverse-phase (RP) and hydrophilic interaction 
liquid chromatography (HILIC) based methodologies have been devel-
oped and validated to analyse different combinations of the first-line 
anti-tuberculosis drugs in clinical samples (Table 1) [14–24]. The se-
lection of appropriate separation technique highly depends on the 
available technical solutions and the ability to adjust chromatographic 
conditions. For example, Gao et al. [16] performed chromatographic 
separation on the Zorbax-SB C18 column, but Zhou et al. [17] used 
Intersil HILIC to separate the same combination of four first-line anti- 
tuberculosis drugs. In contrast, Wang et al. [24] reported that ETB was 
weakly retained on C18 chromatographic columns, but the use of Acq-
uity BEH HILIC column resulted in issues with RIF and its derivate peak 
shapes. The best results were achieved with CAPCELL PAK-ADME – a 
chemically modified RP column [24]. Hee et al. [15] and Song et al. [23] 
also both employed modified C18 chromatographic columns specifically 
designed to retain hydrophilic compounds such as acetylisoniazid and 
isoniazid. 
Regarding sample preparation techniques, the majority of the au-
thors had chosen single-step protein precipitation with organic solvents 
(e.g., acetonitrile, methanol) for plasma sample preparation due to the 
balance between easiness of sample handling and sufficient quality of 
plasma extracts that are compatible with LC-MS/MS system. 
As the metabolite profiling is essential for the correct establishment 
of pharmacokinetic profile and has to be viewed in context with the 
parent drug, a single method is needed to quantify both the first-line 
anti-tuberculosis drugs and their primary metabolites. Only a few of 
the published methods incorporate primary metabolites (Table 1). 
Although the method reported by Sundell et al. [19] comprises the 
broadest spectra of analytes within a single LC-MS/MS method, it lacks 
such important primary metabolites as pyrazine-2-carboxylic acid (the 
active form of PZA) and hepatotoxic 5-hydroxypyrazine-2-carboxylic 
acid. On the other hand, as illustrated in Table 1, the quantification 
ranges used by various methods broadly cover the subtherapeutic con-
centration range of the drug substances but, in some cases, lack the 
middle and upper range of clinically expected plasma concentrations 
described in the literature [3]. Routine sample dilution to fit the cali-
bration curves and a combination of multiple LC-MS/MS methods to 
obtain pharmacokinetic data for all compounds of interest is time- 
consuming, requires large sample volumes and complex technical 
solutions. 
Therefore, this study aimed to develop and validate a single LC-MS/ 
MS method for simultaneous determination of all four first-line anti- 
tuberculosis drugs and their six primary metabolites in human plasma. 
The relevance of the developed method was confirmed by clinical 
sample analysis of TB patients undergoing treatment with first-line anti- 
tuberculosis drugs. 
2. Materials and methods 
2.1. Chemicals and materials 
5-hydroxypyrazine-2-carboxylic acid (5OHPZ2A; purity: 98%), ace-
tylisoniazid (ACIZN; purity: 98%), and 25-desacetylrifampicin (25DRIF; 
purity: 94%) were supplied from Carbosynth (Berkshire, UK). Pyr-
azinamide (PZA; purity: 98%), ethambutol (ETB; purity: 98%), isoniazid 
(IZN; purity: 98%), isonicotinic acid (IZNAC; purity: 99%), pyrazine-2- 
carboxylic acid (PZ2A; purity: 99%), rifampicin (RIF; purity: 99%) 
were from Alfa Aesar (Kandel, Germany). 5-hydroxypyrazinamide 
(5OHPZA; purity: 97%) was purchased from Cymit (Barcelona, Spain), 
phenformin hydrochloride (IS; analytical standard, purity: 98%) was 
from Sigma-Aldrich (Schnelldorf, Germany). Formic acid (FA; MS grade) 
and dimetylsulfoxide (DMSO; HPLC grade) were from Sigma-Aldrich 
(Schnelldorf, Germany). Methanol (MeOH; HPLC grade) was pur-
chased from Merck (Darmstadt, Germany). Water was purified by Milli- 
Q Plus water purification system (Millipore, Molsheim, France). Com-
mercial human plasma (anticoagulant: ethylenediaminetetraacetic acid 
(EDTA), Innovative Research, Novi, MI, USA) and blank human plasma 
samples from national biobank (section 2.6.) were used for the devel-
opment and validation of the assay. 
2.2. UPLC-MS/MS instrumentation and conditions 
An Acquity UPLC H-Class chromatographic system (Waters, Milford, 
MA, USA) coupled to a XEVO TQ-S tandem mass spectrometer (Waters, 
Milford, MA, USA) was used for analysis. The chromatographic sepa-
ration was achieved on the Waters Acquity UPLC BEH C8 column (2.1 ×
75 mm; 1.7 μm). The other columns tested were: Waters Acquity UPLC 
BEH HILIC (2.1 × 50 and 100 mm; 1.7 μm), Acquity UPLC BEH Amide 
(2.1 × 50 and 100 mm; 1.7 μm), and Acquity UPLC BEH C18 (2.1 × 50 
mm; 1.7 μm). The analyte mixture consisting of ten compounds was 
separated using a gradient elution at a flow rate of 0.2 mL/min. The 
mobile phase consisted of 0.1% FA solution (A) and methanol (B). The 
gradient mode was as follows: 0–1 min, 99% A; 1–2.5 min, 99 → 2% A; 
2.5–4.5 min, 2% A, then equilibration to the initial conditions for 5.5 
min. The total run time was 10 min. The volume of injection was 1 µL. 
The autosampler and the column temperature was maintained at 5 ◦C 
and 30 ◦C, respectively. The calibration standards were run in triplicate 
but all samples in duplicate. 
The mass spectrometer was operated in positive electrospray ion-
isation mode (ESI+) with the capillary voltage of 3.0 kV. The source 
temperature was set to 140 ◦C, the desolvation gas (N2) temperature was 
kept at 600 ◦C at a flow rate of 1000 L/h, and the cone gas (N2) flow rate 
was 200 L/h. The multiple reaction monitoring mode (MRM) was used 
for detection and quantification of the analytes. The precursor-to- 
product ion transitions and MRM parameters specified for each com-
pound and IS are listed in Table 2. Data acquisition and analysis were 
performed using MassLynx software and TargetLynx module (version 
4.1., Waters, Milford, MA, USA). 
2.3. Preparation of stock solutions, calibration standards, and quality 
control samples 
The stock solutions of the analytes were prepared in DMSO to a final 
concentration of 10 mg/mL (RIF, 25DRIF, IZN, ACIZN, IZNAC, and ETB) 
or 2 mg/mL (PZA, PZ2A, 5OHPZA, 5OHPZ2A). The internal standard 
was dissolved in the mobile phase (0.1% FA solution) to reach a final 
concentration of 1 mg/mL. The stock solutions were stored at − 20 ◦C. 
The highest calibration standard was prepared by spiking an 
appropriate volume of stock solutions of the analytes into blank plasma. 
The prepared calibration standard was serially diluted with blank 
plasma to obtain six more standards for the construction of the cali-
bration curves. The calibration ranges for all analytes are given in 
Table 3. Quality control (QC) samples were prepared at the lower limit 
of quantification (LLOQ), low (LQC), medium (MQC), and high (HQC) 
concentrations. 
2.4. Sample preparation 
The following single-step protein precipitation with methanol was 
used to prepare calibration standards, QC samples, and clinical samples. 
An aliquot of plasma sample (50 µL) was mixed with 450 µL of freshly 
prepared internal standard solution in methanol (10 μg/mL) and 
centrifuged at 10000 rpm for 10 min at 5 ◦C. Then, 100 µL of the 
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Table 1 
Overview of main characteristics of the published methods offering simultaneous analysis of the first-line anti-tuberculosis drugs with or without primary metabolites 
and comparison to the method developed in this study.  
Reference Analytes Quantification range (µg/mL) Sample volume (V, µL) Sample preparation technique LC column Analysis time, min 
[14] PZA 0.10–30.0 200 LLE Agilent 
Zorbax Eclipse XBD-C18 




[15] RIF 0.025–50.0 20 SPE Agilent 
Zorbax SB-aq 






[16] PZA 0.20–4.00 100 PP Agilent 
Zorbax SB-C18 






[17] PZA 0.004–4.00 100 PP GL Sciences 
Intersil HILIC 






[18] PZA 0.31–39.2 100 PP GL Sciences 
Intersil HILIC 






[19] PZA 0.32–40.0 200 LLE at neutral and acidic conditions GL Sciences 
Intersil HILIC 











PZA 2.00–100 100 PP Waters 
Atlantis HILIC 




IZN 0.10–5.00 50 PP Waters 
Atlantis dC18 




[21] PZA 1.00–100 500 PP Phenomenex 
Gemnini C18 






[22] PZA 2.00–80.0 10 Ultrafiltration Waters 
Atlantis T3 C18 




[23] PZA 5.00–80.0 50 Two-step PP YMC Co. 
Hydrosphere C18 







[24]* PZA 0.005–50.0 100 PP Shiseido 
CAPCELL PAK-ADME 





This study*** PZA 1.17–75.0 50 PP Waters 
Acquity UPLC BEH C8 











STM – streptomycin; RIB – rifabutin; IZN – isoniazid; IZNAC – isonicotinic acid; ACIZN – acetylisoniazid, RIF – rifampicin; 25DRIF – 25-desacetylrifampicin; PZA – 
pyrazinamide; PZ2A – pyrazine-2-carboxylic acid; 5OHPZA – 5-hydroxypyrazinamide; 5OHPZ2A – 5-hydroxypyrazine-2-carboxylic acid; ETB – ethambutol; LLE – 
liquid-liquid extraction; SPE – solid phase extraction; PP – protein precipitation; *quantification ranges are showed only for the first-line anti-tuberculosis drugs; **N/D 
– not determined; ***method developed in this study. 
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supernatant was transferred to a glass vial with 900 µL of mobile phase A 
(0.1% FA solution), briefly vortexed, and used for analysis. 
The IS solution in methanol (10 μg/mL) and the mobile phase A used 
for the sample dilution were stored at 5 ◦C before use. 
2.5. Method validation 
The validation procedure of the developed method was performed 
according to the guidelines of European Medicines Agency on bio-
analytical method validation [25]. 
2.5.1. Selectivity 
The selectivity of the method was evaluated by comparing the signal 
intensity in the blank sample with that in the sample containing IS and 
analytes at the LLOQ level, both prepared in duplicate from six indi-
vidual sources of the matrix. The analyte signal intensity in the blank 
sample should be less than 20% of the analyte signal at the LLOQ level. 
The IS signal intensity in blank sample should not exceed 5% of that in 
analytical sample. 
2.5.2. Calibration curve and lower limit of quantification 
The calibration ranges for PZA, RIF, IZN, ETB, and corresponding 
metabolites (Table 3) were chosen, based on the therapeutic range of the 
particular drug [3]. Generally, seven nonzero calibration standards were 
prepared in blank plasma and analysed in triplicate in three separate 
analytical runs. The seven-point calibration curve for each analyte was 
constructed by plotting the peak area against the analyte concentration 
in the calibration standard and applying an appropriate weighting factor 
(1/x or 1/x2). Since the IS was used for system stability monitoring 
during an analytical run, absolute calibration was applied to calculate 
the analyte concentration. The back-calculated concentrations of the 
calibration standards should be within 15% of the nominal concentra-
tion (at the LLOQ level – 20%). 
The LLOQ was considered the lowest analyte concentration in the 
sample that can be measured with a certain degree of accuracy (within 
20% of the nominal concentration) and precision (coefficient of varia-
tion, CV ≤ 20%). At the LLOQ level, the signal-to-noise ratio should be at 
least 5. 
2.5.3. Accuracy and precision 
The within-run accuracy and precision were demonstrated by anal-
ysis of five replicates of QC samples per concentration level at four 
concentration levels (LLOQ, low, medium, and high). Data from three 
analytical runs performed in three consecutive days were used to 
ascertain between-run accuracy and precision. 
The accuracy was expressed as the difference between the measured 
and nominal concentrations of the QC samples. Assessing within- and 
between-run accuracy, the concentration of QC samples should be 
within 15% of the nominal concentration, except for the LLOQ level, 
where 20% is acceptable. 
The precision was defined as the variance between replicate samples 
and expressed as the coefficient of variation (CV, %). Evaluating within- 
and between-run precision, the CV should not exceed 15% (at the LLOQ 
level CV ≤ 20%). 
2.5.4. Matrix effect 
The matrix effect was determined at two concentration levels (LLOQ 
and high) using matrix factor (MF). The MF was the ratio between the 
analyte peak area in the post-extraction spiked samples and that of 
reference sample prepared in 0.1% FA solution. The post-extraction 
spiked samples were prepared using blank plasma from six different 
individuals. The samples were prepared in duplicate. The CV of MF 
calculated from six different plasma sources should be within 15%. 
2.5.5. Stability 
The analyte stability in human plasma was investigated at different 
storage conditions by analysing QC samples at the LQC and HQC levels. 
For short-term stability, samples were stored on a benchtop at room 
temperature for 1 and 4 h before processed. The long-term stability was 
assessed after QC sample storage at − 20 ◦C for 24 h, 7 days, and 3 
months, respectively. The freeze-thaw stability was evaluated after 
subjecting QC samples to 3 freeze-thaw cycles from the freezer (− 20 ◦C) 
to room temperature in a seven-day period. All QC samples were pre-
pared in duplicate. For the autosampler stability, calibration standards 
were reanalysed after 24 h of storage in the autosampler (5 ◦C). The 
stability of analyte stock solutions was evaluated after stock storage at 
− 20 ◦C for 2 months, while the stability of the IS stock solution was 
assessed after storage at − 20 ◦C for 14 days. All analytes were quantified 
against the freshly prepared calibration standards. The stability was 
calculated from the reference sample concentration and expressed as a 
percentage of the nominal concentration. Stability should be within 15% 
of the nominal concentration. 
2.5.6. Carry-over 
Sample-to-sample carry-over was assessed by injecting the blank 
sample immediately after three consecutive injections of the highest 
calibration standard. Following the highest calibrator, the signal of the 
blank sample should be less than 20% of the analyte signal at LLOQ level 
and 5% of the IS signal. 
2.5.7. Dilution integrity 
The dilution integrity was demonstrated using samples containing 
analytes at a concentration two times the highest calibration standard. 
The samples were diluted before analysis with blank plasma in the ratio 
Table 2 
Optimized mass spectrometric parameters used for detection of the analytes and 












IZN  138.3  121.0 40 10  1.09 
IZNAC  124.3  79.9 30 16  1.20 
ACIZN  180.3  121.1 60 18  1.32 
RIF  821.4  789.3 30 14  4.57  
823.4  791.3 30 14  4.71 
25DRIF  781.4  399.2 50 15  4.62 
PZA  124.3  80.9 20 12  3.62 
PZ2A  125.1  80.9 20 6  2.94 
5OHPZA  140.1  122.9 30 8  2.06 
5OHPZ2A  141.1  54.8 50 15  1.71 
ETB  205.4  116.0 40 18  0.83 
IS  206.2  104.9 30 20  4.10 
IZN – isoniazid; IZNAC – isonicotinic acid; ACIZN – acetylisoniazid, RIF – 
rifampicin; 25DRIF – 25-desacetylrifampicin; PZA – pyrazinamide; PZ2A – 
pyrazine-2-carboxylic acid; 5OHPZA – 5-hydroxypyrazinamide; 5OHPZ2A – 5- 
hydroxypyrazine-2-carboxylic acid; ETB – ethambutol; IS – phenformin (inter-
nal standard). 
Table 3 
Calibration range and LLOQ for the first-line anti-tuberculosis drugs and their 
primary metabolites.  
Compound Calibration range (µg/mL) LLOQ (µg/mL) r2 
IZN 0.16–10.0  0.16  0.995 
IZNAC 0.16–10.0  0.16  0.991 
ACIZN 0.16–10.0  0.16  0.9992 
ETB 0.16–10.0  0.16  0.9998 
RIF 0.47–30.0  0.47  0.996 
25DRIF 0.47–30.0  0.47  0.989 
PZA 1.17–75.0  1.17  0.998 
PZ2A 1.17–75.0  1.17  0.997 
5OHPZA 1.17–75.0  1.17  0.993 
5OHPZ2A 1.17–75.0  2.34  0.996  
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1:5 and 1:10. In total, five replicates per dilution factor were prepared 
and analysed. The dilution of the study samples should not affect the 
accuracy and precision of the results; the accuracy and precision should 
be within 15%. 
2.6. Collection of clinical samples 
Blank human plasma samples (anticoagulant: EDTA) from healthy 
volunteers were received from the national biobank Genome Database 
of Latvian population [26] and used to validate the developed method. 
The clinical applicability of the reported method was assessed by ana-
lysing human plasma samples from newly diagnosed otherwise healthy 
pulmonary TB patients (n = 34) admitted to the Riga East University 
Hospital, Centre of Tuberculosis and Lung Diseases. All patients were 
undergoing WHO-recommended TB treatment regimen [2] and were 
receiving ETB, PZA, RIF, and IZN for ten days before sample collection. 
Blood samples were collected pre-dose (0 h) and 2 h, 6 h after drug 
administration into vacutainers with EDTA. The samples were then 
immediately centrifuged at 4000 rpm (3488g) for 15 min at 4 ◦C to 
separate the plasma. The separated plasma was collected and stored at 
− 70 ◦C until analysis. 
The study was approved by the Central Medical Ethics committee of 
Latvia (approval No: 01-29.1/1), the Ethics Committee of Riga East 
University Hospital (approval No: 24-A/15), and the Ethics Committee 
of Riga Stradins University (approval No: 6-3/1/6). 
3. Results and discussion 
3.1. Optimisation of UPLC-MS/MS conditions 
Both HILIC and RP modes were tested for separation of the analytes. 
In the experiments conducted, the mobile phase organic constituent was 
acetonitrile, methanol, or isopropanol. Mobile phase additives (i.e., FA, 
ammonium acetate, ammonia hydroxide, acetic acid) were used to 
improve the peak shape and retention times for better separation of the 
analytes. The representative chromatograms are shown in (Supple-
mentary Fig. 1). 
HILIC separation mode was tried on Acquity UPLC BEH HILIC and 
Acquity UPLC BEH Amide columns. The analytes of interest were weakly 
retained on the BEH HILIC column and eluted within 3 min, even using 
100 mm column. Sundell et al. [19] achieved optimal results under 
similar conditions, but, in our hands, observed peak overlapping due to 
early analyte elution was unacceptable. The use of the BEH Amide col-
umn allowed to achieve sufficient retention for all analytes. The pro-
longation of retention times for polar analytes on amide columns, in 
comparison to chemically unmodified HILIC stationary phases, was 
confirmed earlier and might be explained by differences in dominating 
type of interactions between the stationary phase and analytes [27]. 
However, RIF, 25DRIF, and ETB yielded poor peak shapes and attempts 
to improve that by addition of ammonium acetate (10–50 mM) to the 
mobile phase as suggested by the other authors [17,18] caused severe 
ionisation suppression of PZ2A and 5OHPZ2A. Priyanka et al. [14] 
experimentally proved that the ionisation of acidic PZA metabolites is 
either sensitive to mobile phase pH changes. In our hands, the analysis 
on the BEH Amide column was possible only in two mobile phase sys-
tems with opposite pH. Therefore, the optimisation of the chromato-
graphic conditions on this column was discontinued. 
Acquity UPLC BEH C18 and BEH C8 columns were applied in RP 
mode. The most polar analytes (ETB, IZN, and IZNAC) eluted in void 
volume on the BEH C18 column. Application of highly aqueous initial 
mobile phase composition (up to 99% water) did not result in sufficient 
retention of these analytes. The published data [15,23,24] suggested 
that the use of chemically modified C18 columns could facilitate chro-
matographic separation of the analytes. However, considerably better 
results were achieved on the unmodified BEH C8 column. The shorter 
alkyl chains are less hydrophobic and thus enhanced retention of polar 
constitutes at similar conditions. The further adjustment of chromato-
graphic conditions (e.g., mobile phase composition, flow rate) was 
directed towards the separating overlapping peaks – IZN and metabo-
lites, 5OHPZ2A and 5OHPZA. An increase in column temperature would 
again result in shortening of retention times and for this reason, was not 
considered. The mobile phase gradient (0.1% FA solution (A) and 
methanol (B); 99 → 2% A) at a flow rate of 0.2 mL/min was suitable for 
the separation of the analyte mixture (Fig. 1). At the given conditions, 
ionisation issues or peak splitting were not observed. The sensitivity of 
the developed method allowed us to reduce the injection volume to 1 μL. 
If the injection volume was increased, peaks tended to broaden, and 
column overload was expected. Although the analytes were separated in 
less than 5 min, the total run time was extended to 10 min for system 
equilibration. 
ESI+ mass spectra was acquired for all analytes. The most abundant 
fragments were chosen from product ion spectra to set appropriate MRM 
transitions. Precursor-product ion pairs and optimised MRM parameters 
for ten analytes and IS are shown in Table 2. 
Optimised chromatographic conditions prevented peak overlapping 
and enabled accurate quantification of the analytes. Due to the forma-
tion of rifampicin quinone, two RIF peaks were observed, as reported in 
the literature [28]. Thereby, two ion-transitions were used for accurate 
rifampicin quantification. 
3.2. Sample preparation 
Literature reports the application of liquid-liquid extraction (LLE), 
solid-phase extraction (SPE), and protein precipitation (PP) techniques 
for sample pre-treatment (Table 1). Preliminary experiments of LLE with 
ethyl acetate resulted in low recovery for PZ2A and 5OHPZ2A, and in-
terferences with unseparated plasma components for the other analytes 
were observed. The introduction of polar acidic pyrazinamide metabo-
lites in the analyte mixture required sample fractionation to achieve 
optimal recovery for acidic and basic compounds, as suggested by the 
other authors [14,19]. Similarly, the HybridSPETM-Phospholipid Ultra 
cartridge (Supelco) retained both polar analytes due possible Lewis acid- 
base interaction on the surface of the stationary phase under chosen 
conditions. Then, single-step PP with methanol and acetonitrile (with or 
without FA or ammonium hydroxide additive) were investigated. The 
PP with methanol without the use of any additives successfully reduced 
the excessive amount of endogenous matrix components in the final 
sample and provided consistent results, as shown in Section 3.3.4. The 
applied PP method was simple, fast, and cost-effective, allowing high- 
throughput analysis of study samples. 
3.3. Method validation 
3.3.1. Selectivity 
In the MRM chromatograms shown in Fig. 2 representing the blank 
plasma sample and the first calibration standard containing IS and 
analytes at LLOQ level, it is seen that no potentially interfering signals at 
the expected retention time of the analytes and IS appear in the indi-
vidual MRM channels of the blank plasma sample. If comparing the 
analytical signal of blank plasma samples to their equivalents with IS 
and analytes at LLOQ level, it was found that the signal intensity of 
5OHPZ2A at LLOQ level is lower than expected, and the signal of blank 
matrix in this MRM channel comprised 25% of the analyte signal. 
3.3.2. Calibration curve and lower limit of quantification 
The seven-point calibration curves were obtained by plotting the 
peak area versus analyte concentration in the corresponding calibration 
standard. The results confirmed a linear analytical response in calibra-
tion ranges given in Table 2 with the correlation coefficients (r2) in the 
range of 0.989–0.9998 when weighting factors 1/x or 1/x2 applied 
(Table 3). The back-calculated concentrations for the calibration stan-
dards were 86.3–108.7% (at the LLOQ level 83.7–106.1%) 
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(Supplementary Table 1). 
The LLOQ for all analytes was set at a concentration of the lowest 
calibration standard where the CV between replicate samples was in the 
range 0.3–12.9% but signal-to-noise ratio ≥ 5. Considering the low 
signal intensity of 5OHPZ2A at the LLOQ level, it was decided to set the 
second level calibration standard as LLOQ, where the signal-to-noise 
ratio was >5. 
The chosen quantification ranges for all first-line anti-tuberculosis 
drugs correspond to the theoretically expected plasma concentrations 
[3] and are broader than those reported in the majority of previous 
studies (Table 1). The quantification ranges for metabolites were 
derived from the respective quantification range of the parent drug. As a 
consequence of expanding quantification ranges, the LLOQ values tend 
to be slightly higher. However, quantitation below the therapeutic 
window still is possible with a sufficient degree of accuracy and 
precision. 
3.3.3. Accuracy and precision 
The within- and between-run accuracy and precision were evaluated 
at four concentration levels (LLOQ, LQC, MQC, and HQC). The results 
are given in Table 4. The within-run accuracy in all concentration levels 
was between 87.2 and 113.6%. The CV between replicate samples (n =
5) at all concentration levels was 1.6–14.9%, except for LLOQ level, 
where 16.6% for IZNAC and 17.3% for 25DRIF complied with the 
Fig. 1. Overlay plot of MRM chromatograms (seventh calibration standard, STD7). The chromatographic separation of the analyte mixture was achieved on BEH C8 
column within 5 min. The total run time was extended to 10 min for system equilibration. A – ETB (0.83); B – IZN (1.09); C – IZNAC (1.20); D – ACIZN (1.32); E – 
5OHPZ2A (1.71); F – 5OHPZA (2.06); G – PZ2A (2.94); H – PZA (3.62); I – IS (4.10); J, L – RIF (4.57, 4.71); K – 25DRIF (4.62). 
Fig. 2. Representative MRM chromatograms of the blank plasma sample (Blank) and the first calibration standard (STD1), containing analytes at LLOQ level and IS.  
A. Kivrane et al.                                                                                                                                                                                                                                 
Journal of Chromatography B 1185 (2021) 122986
7
requirements. The between-run accuracy and precision were calculated 
as the average of three analytical runs performed on three consecutive 
days and ranged 91.1–109.3% and 3.5–13.3%, respectively. 
3.3.4. Matrix effect 
Matrix effect was assessed at LQC and HQC concentration levels 
using MF calculated for six different matrix sources. The mean MF for 
most of the analytes was in the range of 0.9–1.1, thus exhibiting a 
minimal contribution of the matrix to ion suppression or enhancement 
(Table 5). The MF < 0.5 for ETB and IZN indicated significant ion sup-
pression by unseparated matrix components. The response of IZNAC at 
the LQC level varied depending on the matrix source; the CV between six 
different matrix sources was 21.8%. However, the results of linearity, 
accuracy, and precision confirmed that observed inconsistency did not 
affect the quantification of the IZNAC. 
3.3.5. Stability 
The obtained results of analyte stability in human plasma at various 
storage conditions are summarized in Table 6. Accordingly, all tested 
compounds were found to be stable in the human plasma samples at 
room temperature up to 1 h, but after 4 h, a significant reduction in 
25DRIF, IZN, and IZNAC concentrations was observed. The samples 
were stable when stored at − 20 ◦C for 24 h; storage time extension to 7 
days resulted in the IZN and IZNAC concentration decrease by more than 
15%. Moreover, the plasma sample exposure to three freeze-thaw cycles 
in 7 days contributed to the degradation of RIF and 5OHPZ2A. The long- 
Table 4 
The within- and between-run accuracy and precision for the first-line anti-tuberculosis drugs and their primary metabolites in human plasma.  
Compound QC level Nominal concentration (µg/mL) Within-run Between-run 
Accuracy (%) Precision (CV, %) Accuracy (%) Precision (CV, %) 
IZN LLOQ  0.16  108.0  12.8  101.9  8.7 
LQC  0.40  98.7  11.5  97.0  7.4 
MQC  4.00  92.9  6.8  94.5  7.4 
HQC  8.00  99.0  9.2  95.5  9.6 
IZNAC LLOQ  0.16  95.2  16.6  97.2  12.1 
LQC  0.40  105.4  8.6  101.7  8.3 
MQC  4.00  94.9  8.4  97.7  6.8 
HQC  8.00  97.5  5.4  99.6  4.7 
ACIZN LLOQ  0.16  94.1  5.3  91.1  6.8 
LQC  0.40  93.7  4.0  97.4  5.2 
MQC  4.00  91.1  3.9  96.3  4.3 
HQC  8.00  90.2  3.7  92.5  5.3 
ETB LLOQ  0.16  109.3  4.8  99.3  7.6 
LQC  0.40  104.3  5.4  97.0  5.9 
MQC  4.00  97.1  5.8  04.0  5.2 
HQC  8.00  96.2  4.7  94.4  5.2 
RIF LLOQ  0.48  113.6  6.1  109.3  5.6 
LQC  1.20  104.7  3.2  103.5  5.4 
MQC  12.0  107.1  3.1  104.6  3.5 
HQC  24.0  101.4  3.3  100.8  4.7 
25DRIF LLOQ  0.48  100.7  10.0  98.7  13.3 
LQC  1.20  91.1  12.5  97.5  10.0 
MQC  12.0  92.5  6.0  98.0  6.0 
HQC  24.0  102.5  4.5  97.1  6.4 
PZA LLOQ  1.20  96.4  11.2  93.7  8.4 
LQC  3.00  99.0  9.3  100.2  6.6 
MQC  30.0  93.3  9.4  96.7  5.6 
HQC  60.0  89.5  9.2  91.7  6.4 
PZ2A LLOQ  1.20  95.5  9.5  93.8  11.0 
LQC  3.00  103.1  7.1  102.4  7.3 
MQC  30.0  96.9  3.8  98.3  3.8 
HQC  60.0  94.0  3.3  93.5  4.7 
5OHPZA LLOQ  1.20  99.1  7.9  93.4  7.9 
LQC  3.00  107.3  5.9  103.9  5.3 
MQC  30.0  97.2  4.4  97.8  3.8 
HQC  60.0  89.4  4.5  91.4  5.2 
5OHPZ2A LLOQ  1.20  88.0  14.9  92.2  11.5 
LQC  3.00  105.4  9.9  102.2  7.6 
MQC  30.0  102.9  5.8  99.3  4.4 
HQC  60.0  96.3  5.1  93.3  4.8  
Table 5 
The calculated matrix factors (MF) for the analytes and IS at the low and high QC 
levels.  
Compound QC level MF (mean ± SD; n = 6) CV (%) 
IZN LQC 0.4 ± 0.03  6.3 
HQC 1.3 ± 0.1  6.6 
IZNAC LQC 0.6 ± 0.1  21.8 
HQC 0.8 ± 0.1  11.9 
ACIZN LQC 1.1 ± 0.1  5.1 
HQC 1.1 ± 0.04  3.5 
ETB LQC 0.4 ± 0.02  3.8 
HQC 0.5 ± 0.02  3.9 
RIF LQC 1.1 ± 0.1  6.6 
HQC 0.8 ± 0.04  5.0 
25DRIF LQC 1.3 ± 0.2  14.2 
HQC 1.1 ± 0.2  17.5 
PZA LQC 1.0 ± 0.02  1.7 
HQC 1.0 ± 0.01  0.9 
PZ2A LQC 1.1 ± 0.1  6.0 
HQC 1.0 ± 0.03  2.5 
5OHPZA LQC 0.9 ± 0.1  9.2 
HQC 1.0 ± 0.1  8.2 
5OHPZ2A LQC 1.0 ± 0.04  3.7 
HQC 1.0 ± 0.02  2.2 
IS LQC 0.7 ± 0.1  7.3 
HQC 0.8 ± 0.05  6.6  
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term stability test at − 20 ◦C for 3 months caused substantial degradation 
of the analytes. Similar findings regarding the limited plasma stability of 
IZN, RIF and their metabolites were previously mentioned by the other 
authors [18,21,22]. Based on these results, it is recommended that 
plasma samples should be processed within 4 h after collection. If 
necessary, temporary storage at − 20 ◦C up to 24 h is acceptable. 
The IZNAC and 25DRIF were found to be unstable in the autosampler 
(stability 71.6–81.3%), as the stability of the other analytes ranged from 
86.1 to 100.1% and complied with the requirements. The IS stock so-
lution remained unchanged for 14 days at − 20 ◦C, whereas the 5OHPZA 
stock solution was the only exhibiting a concentration reduction of more 
than 15% when stored at − 20 ◦C for 2 months. 
3.3.6. Carry-over 
The signal of the blank plasma sample following the highest cali-
bration standard ranged from 0.9 to 20.3%. The IS signal in the corre-
sponding MRM channel was not detected at all. As a result, it was 
assumed that significant carry-over between samples did not occur. 
3.3.7. Dilution integrity 
Dilution integrity was demonstrated by analysing the samples con-
taining analytes above HQC before 5- and 10-fold dilution. When per-
forming analysis of processed samples, it was found that the CV between 
replicate samples (n = 6) was between 3.6 and 10.3%. In contrast, the 
accuracy for ETB and IZN was between 78.4 and 83.7%, but for the 
remaining analytes was within 15% and met the acceptance criteria. The 
obtained results suggest that study samples with analyte concentration 
above HQC can be diluted before sample preparation, apart from cases 
when ETB and IZN exceed the upper limit of quantification. 
3.4. Clinical application 
The validated method was applied to the human plasma samples 
from otherwise healthy pulmonary TB patients (n = 34) subjected to the 
TB treatment regimen with four first-line anti-tuberculosis drugs 10 days 
before sample collection. Concentrations of four drug substances and six 
metabolites were measured before drug administration (0 h), 2 and 6 h 
after receiving a single dose of anti-tuberculosis drugs. The mean con-
centrations are given in Table 7. Overall, the measured plasma 
concentrations were within the analytical range of the proposed method. 
It was possible to determine baseline concentrations before drug intake 
and estimate whether plasma concentrations confirm the therapeutic 
window reported in the literature [3]. The observed subtherapeutic 
plasma concentrations of the RIF (<8 µg/mL) and IZN (<3 µg/mL) 2 h 
after drug intake in the study population were consistent with the pre-
vious findings and can be explained with pharmacokinetic variability 
among TB patients [28–31]. The auto-induction capacity of RIF over the 
period of treatment tends to reduce its exposure, whereas IZN plasma 
concentration mostly depends on the N-acetyltransferase 2 (NAT2) 
enzymatic activity [10,32,33]. The full interpretation of the study re-
sults will be published in a separate paper. 
To date, this is the first report on the LC-MS/MS method that allows 
determining the full primary metabolite profile of anti-tuberculosis 
drugs in human plasma within a single run. Therefore, the developed 
method can be employed in population-scale studies to enhance the 
knowledge of the pharmacokinetics of anti-tuberculosis drugs and for 
the therapeutic drug monitoring purposes. The offered method can be 
either employed in clinical practice, as the obtained pharmacokinetic 
data would justify the need for transition from standardized to indi-
vidualized TB therapy. 
4. Conclusions 
The validation results confirmed the performance of the reported 
method, thus guaranteeing the quality of the results. The main advan-
tages are the requirement of small sample volume for analysis, simple 
sample pre-treatment procedure, and the ability to analyse all four first- 
line anti-tuberculosis drugs and all six primary metabolites within a 
single run to enhance the utility of pharmacokinetic studies. Besides, the 
chosen quantification ranges fully cover clinically expected plasma 
concentrations, thereby reducing the need for sample dilution before the 
pre-treatment procedure. The clinical sample analysis gave an insight 
into the method’s clinical applicability, where the aim was to determine 
TB drug exposure in the study population. The obtained results highlight 
the importance of future studies addressing issues related to the efficacy 
of TB treatment. 
Table 6 




Stored at RT* 
for: 
Stored at − 20 ◦C for: Freeze-thaw 
(3 cycles, 
− 20 ◦C, 7 




IZN LQC  102.9  82.2  87.2  82.8  56.4  73.1 
HQC  89.9  93.0  100.3  84.0  64.7  93.1 
IZNAC LQC  93.1  78.1  94.3  91.0  95.4  89.1 
HQC  90.3  72.3  98.9  75.0  80.3  91.8 
ACIZN LQC  95.7  88.8  84.7  98.5  80.6  86.6 
HQC  95.2  95.0  98.6  94.3  91.3  101.7 
RIF LQC  95.4  89.9  90.9  97.0  94.4  75.8 
HQC  94.5  94.3  92.7  94.8  90.3  87.5 
25DRIF LQC  95.6  89.3  89.5  94.5  81.3  92.4 
HQC  89.4  76.7  93.6  86.3  77.7  94.8 
PZA LQC  97.8  94.2  86.9  90.8  112.1  90.3 
HQC  95.4  92.9  99.4  96.8  101.7  98.3 
PZ2A LQC  92.0  94.5  88.2  93.7  116.5  86.6 
HQC  91.5  91.6  98.3  93.0  103.6  97.3 
5OHPZA LQC  98.8  92.8  84.9  97.3  148.6  87.6 
HQC  94.5  90.9  96.4  92.5  138.5  93.7 
5OHPZ2A LQC  94.2  86.1  89.7  98.4  83.7  76.5 
HQC  93.5  90.6  99.3  92.9  80.6  87.0 
ETB LQC  98.1  97.3  88.5  105.0  103.9  94.3 
HQC  100.0  96.2  98.7  98.2  100.9  100.8 
*RT – room temperature 
Table 7 
Concentration of the first-line anti-tuberculosis drugs and six primary metabo-
lites in TB patient plasma (n = 34) pre-dose (0 h), 2 and 6 h after drug 
administration.  
Compound Measured concentration (μg/mL, mean 
± SD; n = 34) 




2 h post- 
dose 








































































N/A* – not applicable. 
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